Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Consun Pharmaceutical Group Limited (C1P.F)

Compare
0.9100
-0.0600
(-6.19%)
At close: April 4 at 8:05:45 AM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Meng An CEO & Executive Chairman 2.46M -- 1971
Ms. Yujun Chen Chief Financial Officer 24.87k -- 1980
Prof. Quan Zhu Chief Scientist & Executive Director 92.27k -- 1940
Lei Zhou Assistant President -- -- --
Mr. Haien Gao Board Secretary -- -- 1969
Mr. Guorong Guo Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd -- -- --
Ms. Lianhui Chen Chairman & GM of Consun Pharmaceutical (Horgos) Co., LTD. -- -- --

Consun Pharmaceutical Group Limited

71, Dongpeng Avenue
Eastern section Guangzhou Eco & Tech Dev Zn
Guangzhou
China
86 20 8226 4529 https://www.chinaconsun.com
Sector: 
Healthcare
Full Time Employees: 
3,164

Description

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Corporate Governance

Consun Pharmaceutical Group Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 26, 2025 at 4:10 AM UTC

Consun Pharmaceutical Group Limited Earnings Date

June 10, 2025 at 12:00 AM UTC

Ex-Dividend Date

Recent Events

Related Tickers